U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07413341) titled 'A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases' on Feb. 02.
Brief Summary: This is an open-label, dose escalation study in patients with relapsed and refractory autoimmune diseases. Study drug, TI-0032-III injection, is composed of lipid nanoparticles (LNPs) targeting T cells that encapsulate circular RNA encoding the CD19 chimeric antigen receptor (CAR), which is a therapeutic biological product. It is clinically intended for the treatment of various relapsed and refractory B cell-related autoimmune diseases, such as systemic lupus erythematosus, sjogren's syndrome, systemic s...